Viridian Therapeutics

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Signal Genetics, Inc. is a commercial-stage molecular diagnostics company that specializes in providing diagnostic services aimed at aiding physicians in making informed treatment decisions for cancer patients. Founded in April 2010, the company holds an exclusive license for research conducted at the University of Arkansas for Medical Sciences, which has accumulated over 30 years of clinical data from nearly 10,000 multiple myeloma patients. This extensive research underpins Signal Genetics' flagship product, MyPRS® (Myeloma Prognostic Risk Signature), which offers insights into patient prognosis and risk assessment in multiple myeloma. Through its innovative approach, Signal Genetics seeks to improve patient outcomes by utilizing advanced molecular diagnostics in oncology.